Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 8/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 3/20 | 0.49 |
| ▸ | BACE1 | P56817 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9714210 | 0.84 | ACHE (0.67) | KDM4EGAAACHEMAPK1BCHE | |
| SCHEMBL6176132 | 0.83 | KDM4E (0.65) | KDM4EGAAACHEMAPK1BCHE | |
| SCHEMBL5830478 | 0.83 | KDM4E (0.69) | KDM4EGAAACHEMAPK1CHRM4 | |
| SCHEMBL6153478 | 0.80 | KDM4E (0.60) | KDM4EGAAACHECHRM2BCHE | |
| SCHEMBL13419693 | 0.79 | KDM4E (0.74) | KDM4EGAAACHEMAPK1BCHE | |
| SCHEMBL13419300 | 0.78 | GAA (0.72) | KDM4EGAAACHEMAPK1BCHE | |
| SCHEMBL9731324 | 0.77 | ACHE (0.47) | ACHECHRM4CHRM2BCHEBACE1 | |
| SCHEMBL6153601 | 0.77 | KDM4E (0.62) | KDM4EGAAMAPK1SIGMAR1 | |
| SCHEMBL6154441 | 0.76 | ACHE (0.57) | KDM4EGAAACHEBCHEBACE1 | |
| SCHEMBL7286870 | 0.75 | KDM4E (0.67) | KDM4EGAAACHEBCHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | KDM4E 2017/4885GAA 2875/4885ACHE 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.